혈액제제 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, blood preparation market size in 2026 is estimated at USD 59.81 billion, growing from 2025 value of USD 56.55 billion with 2031 projections showing USD 79.19 billion, growing at 5.76% CAGR over 2026-2031.

This report is Segmented by Product Type (Whole Blood, Blood Components, and Blood Derivatives), Blood Thinning Agents (Anticoagulants, and More), Application (Thrombocytosis, and More), End User (Hospitals & Surgical Centers, and More), Geography (North America, Europe, Asia-Pacific, The Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Blood Preparation Market Trends and Insights

Increasing Global Surgical Procedures Volume

Elective and trauma-related surgeries are rebounding in 2025, boosting demand for red-cell concentrates and plasma components. Hospitals in the United States increased orthopedic procedure counts by 8% year-on-year, prompting upgrades in component storage and rapid-type testing. Similar momentum is visible in Western Europe, where minimally invasive techniques encourage outpatient surgeries that still require pre-operative blood matching. Automated cross-matching analyzers and digital blood-bank software shorten turnaround times, improving utilization rates for every donated unit. These developments strengthen revenue visibility for the blood preparation market.

Growing Prevalence of Chronic and Hematologic Disorders

Chronic kidney disease, hematologic cancers, and hemophilia continue to rise across Asia-Pacific, expanding recurring demand for plasma-derived immunoglobulins and coagulation factors. Government reimbursement lists in China and India now include subcutaneous immunoglobulin therapy, accelerating patient access. Multinationals respond by adding fractionation lines and donor centers, while domestic firms partner for technology transfer. The broad disease burden ensures long-term pull for blood derivatives, reinforcing sustainable growth for the blood preparation market.

Risk of Transfusion-Transmitted Infections

Studies in Uganda reported 13.8% prevalence of transfusion-transmitted infections among donors, with HBV and HCV notably high. While pathogen-reduction systems cut malaria transmission risk by 87%, budget limitations hinder adoption where the threat is greatest. International-donor agencies fund pilot programs, yet scalability lags behind infection growth. The persistent gap emphasizes the need for affordable sterilization, tempering absolute growth of the blood preparation market.

Other drivers and restraints analyzed in the detailed report include:

1. Rising Government Support for Blood Collection Infrastructure
2. Advancements in Blood Screening and Processing Technologies
3. High Cost of Advanced Blood Preparation Technologies

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Blood derivatives held 47.98% of 2025 revenue, anchored by strong immunoglobulin and coagulation factor demand. The pulmonary embolism segment accounted for 27.31% share of the blood preparation market size in 2025, supporting derivative consumption in acute settings. CSL Behring logged 20% sales growth for immunoglobulins, aided by a 22% drop in plasma collection cost per liter, illustrating scale economics that favor large fractionators. Automated systems such as Reveos drive 8.12% CAGR for blood components, delivering higher platelet and red-cell yields per unit, lowering wastage, and extending storage times from 42 to 63 days through super-cooling preservation. Increasing hospital adoption of component-specific transfusion protocols sustains this expansion for the blood preparation market.

The derivatives pipeline remains buoyant. Grifols projects USD 1 billion cumulative sales for Yimmugo over seven years post-FDA approval. European governments aim to reach 80% self-sufficiency in albumin by 2030, stimulating domestic contract fractionation programs. Parallel advances in whole-blood robotics and artificial substitutes offer long-range alternatives but will take time to displace established derivatives. Consequently, derivatives retain leadership even as component innovation elevates the efficiency and profitability of the blood preparation market.

Anticoagulants represented 60.88% of 2025 revenue, reflecting entrenched clinical guidelines and physician familiarity. Abelacimab, a factor XI inhibitor, reduced bleeding by 67% versus rivaroxaban in atrial-fibrillation trials, propelling platelet-aggregation inhibitor growth at an 8.29% CAGR. Apixaban remained Australia's most prescribed oral anticoagulant, costing the health system USD 500 million in 2024. The pulmonary embolism segment captured 27.31% share of the blood preparation market, reinforcing anticoagulant volumes across emergency and chronic settings.

Four-factor prothrombin complex concentrate is displacing frozen plasma during cardiac surgery, lowering major bleeding by nearly 50%. Fibrinolytics hold steady demand but face increasing competition from recombinant hemostatic drugs that shorten infusion times. As factor XI agents enter late-stage development, prescribing patterns may pivot, but established anticoagulants will continue to anchor revenue for the blood preparation market during the forecast horizon.

Complete Report Scope:

• By Product Type
  • Whole Blood
  • Blood Components
    • Red Blood Cells
    • Platelets
    • Plasma
  • Blood Derivatives
    • Immunoglobulins
    • Coagulation Factors VIII & IX
    • Albumin
• By Blood Thinning Agents
  • Anticoagulants
  • Fibrinolytics
  • Platelet Aggregation Inhibitors
• By Application
  • Thrombocytosis
  • Pulmonary Embolism
  • Renal Impairment
  • Other Applications
• By End User
  • Hospitals & Surgical Centers
  • Blood & Plasma Banks
  • Other End Users
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America retained 38.12% of 2025 revenue, underpinned by 350 CSL Plasma donor centers and rapid uptake of the Rika collection system, which cuts donation time by 15 minutes. The region's elaborate regulatory agenda, with five blood-focused guidance documents slated for 2025, accelerates technology approval and adoption. Yet climate disruptions dent supply: the American Red Cross saw a 25% inventory drop in July 2024 during extreme heat and storms.

Asia-Pacific registers the highest 7.14% CAGR. Terumo's USD 15 million Hangzhou plant enhances local production, while Indonesia's plasma-fractionation project fast-tracks regional self-sufficiency. Japan's artificial-blood program at Nara Medical University could revolutionize emergency transfusion with two-year shelf life and universal compatibility. Europe focuses on autonomy under the new SoHO regulation, requiring 2 million extra donors and common quality standards across member states. The United Kingdom is on track for 25% immunoglobulin self-sufficiency by 2025, aided by domestic fractionation contracts gov.uk. Sanquin's adoption of automated processing in the Netherlands demonstrates how technology reduces dependence on incremental donations. These geographic dynamics collectively reinforce a balanced global outlook for the blood preparation market.

1. CSL Behring
2. Takeda Pharmaceutical Co.
3. Baxter
4. Grifols
5. Octapharma
6. Pfizer
7. Bayer
8. Sanofi
9. Bristol-Myers Squibb
10. Boehringer Ingelheim
11. Daiichi Sankyo
12. GlaxoSmithKline
13. Leo Pharma
14. Abbott Laboratories
15. Haemonetics
16. Terumo
17. Fresenius
18. Medtronic PLC (Blood Management)
19. American Red Cross
20. Kedrion Biopharma

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope Of The Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Increasing Global Surgical Procedures Volume
  • 4.2.2 Growing Prevalence of Chronic And Hematologic Disorders
  • 4.2.3 Rising Government Support for Blood Collection Infrastructure
  • 4.2.4 Advancements in Blood Screening and Processing Technologies
  • 4.2.5 Expansion of Plasma-Derived Therapeutics Portfolio
  • 4.2.6 Growing Adoption of Novel Oral Anticoagulants
• 4.3 Market Restraints
  • 4.3.1 Risk of Transfusion-Transmitted Infections
  • 4.3.2 High Cost of Advanced Blood Preparation Technologies
  • 4.3.3 Supply Chain Constraints for Donor Plasma and Heparin
  • 4.3.4 Inadequate Cold Chain and Storage Facilities in Developing Regions
• 4.4 Regulatory Landscape
• 4.5 Porter's Five Forces Analysis
  • 4.5.1 Threat Of New Entrants
  • 4.5.2 Bargaining Power Of Buyers
  • 4.5.3 Bargaining Power Of Suppliers
  • 4.5.4 Threat Of Substitutes
  • 4.5.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Product Type
  • 5.1.1 Whole Blood
  • 5.1.2 Blood Components
    • 5.1.2.1 Red Blood Cells
    • 5.1.2.2 Platelets
    • 5.1.2.3 Plasma
  • 5.1.3 Blood Derivatives
    • 5.1.3.1 Immunoglobulins
    • 5.1.3.2 Coagulation Factors VIII & IX
    • 5.1.3.3 Albumin
• 5.2 By Blood Thinning Agents
  • 5.2.1 Anticoagulants
  • 5.2.2 Fibrinolytics
  • 5.2.3 Platelet Aggregation Inhibitors
• 5.3 By Application
  • 5.3.1 Thrombocytosis
  • 5.3.2 Pulmonary Embolism
  • 5.3.3 Renal Impairment
  • 5.3.4 Other Applications
• 5.4 By End User
  • 5.4.1 Hospitals & Surgical Centers
  • 5.4.2 Blood & Plasma Banks
  • 5.4.3 Other End Users
• 5.5 Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East & Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East & Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Business Segments, Financials, Headcount, Key Information, Market Rank, Market Share, Products and Services, and analysis of Recent Developments)
  • 6.3.1 CSL Behring
  • 6.3.2 Takeda Pharmaceutical Co.
  • 6.3.3 Baxter International
  • 6.3.4 Grifols S.A
  • 6.3.5 Octapharma AG
  • 6.3.6 Pfizer Inc
  • 6.3.7 Bayer AG
  • 6.3.8 Sanofi S.A
  • 6.3.9 Bristol-Myers Squibb
  • 6.3.10 Boehringer Ingelheim
  • 6.3.11 Daiichi Sankyo
  • 6.3.12 GlaxoSmithKline PLC
  • 6.3.13 Leo Pharma
  • 6.3.14 Abbott Laboratories
  • 6.3.15 Haemonetics Corporation
  • 6.3.16 Terumo BCT Inc.
  • 6.3.17 Fresenius Kabi
  • 6.3.18 Medtronic PLC (Blood Management)
  • 6.3.19 American Red Cross
  • 6.3.20 Kedrion S.p.A.

7 Market Opportunities & Future Outlook

• 7.1 White-Space & Unmet-Need Assessment